SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing significant downward pressure as market participants debate the long-term impact of its massive AI infrastructure debt, rising capital expenditures, and a recent credit rating downgrade. Despite strong cloud backlog numbers, the community is deeply divided between those viewing the current sell-off as a compelling long-term accumulation opportunity and those concerned that the stock faces further deterioration or insolvency risks.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is experiencing extreme volatility driven by aggressive retail leverage in the South Korean market and anticipation surrounding an upcoming 20-for-1 forward stock split. Investors are closely monitoring the interplay between massive institutional rebalancing, speculative margin-based trading, and the broader impact of global semiconductor demand.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is experiencing significant downward pressure as investors rotate out of precious metals amidst shifting Federal Reserve rate expectations and broader market volatility. The community is actively debating whether current support levels offer a genuine accumulation opportunity or if the stock faces further downside risk as macroeconomic conditions and geopolitical tensions continue to reshape the investment landscape.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio is trending as investors react to the company's recent public offering of common stock and pre-funded warrants, with community discussion intensely focused on how this dilution will impact the share price versus the stock's significant momentum following positive clinical data for bempikibart. Traders are actively debating the timing of the offering and whether the clinical win justifies higher valuations or if the stock is primed for a sell-off as the market re-prices based on the increased share count.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is facing heightened volatility and selling pressure as the market reacts to renewed U.S. military operations against Iran and the reinstatement of a maritime blockade, which has sent energy prices spiking. While technical traders are closely monitoring key support levels and pivot points, the broader community is deeply divided between bearish sentiment fueled by geopolitical uncertainty and bullish traders positioning for potential relief bounces tied to upcoming CPI reports and major bank earnings.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is trending as market sentiment shifts toward its AI and autonomous driving segments, with community discussion heavily focused on the potential value of its Kunlunxin chip subsidiary IPO and the company's competitive position in the agentic AI landscape. While the stock has seen volatility linked to broad China tech rotation and regulatory noise, bullish traders are highlighting recent fundamental growth in cloud and AI infrastructure as reasons for a long-term structural re-rating.

Factorial Energy, Inc. engages in the development and commercialization of solid-state battery technologies. Its platforms include FEST and Solstice, designed to deliver high-performance, scalable battery solutions for applications in drones, robotics, automotive, and other advanced mobility sectors. The company is headquartered in Billerica, MA.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy Inc

Factorial Energy is experiencing high volatility as investors react to a strategic drone partnership and flight test news, leading to intense debate over the company's long-term commercial potential versus concerns about short-term dilution. The community is actively tracking the stock's sharp price swings and divided perspectives on whether the current dip represents a buying opportunity or a deeper correction.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending as investors weigh promising new 3rd-party validation data regarding its GaN-on-Silicon performance breakthroughs against the company's long-standing struggle to convert technical test results into sustained commercial revenue. Community discussion remains polarized, with bulls pointing toward potential upcoming deals and foundry integration as major catalysts, while bears highlight persistent dilution, management's track record of missed timelines, and the lack of material commercial royalties after two decades of R&D.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility as investors debate the impact of its pending LivePerson merger and significant short interest. While bulls highlight long-term growth in edge-AI partnerships and Gartner leadership recognition, bears remain focused on persistent dilution concerns and high cash burn rates.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors react to the companys strategic rollout of its proprietary DKeX prediction market exchange and a high-profile long position disclosure from Michael Burry. The community is heavily debating the potential impact of prediction market regulation, the platform's long-term competitive positioning against rivals like Kalshi, and whether current sports betting volume will drive a significant earnings beat.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dow, S&P 500 Futures Slip While Nasdaq Holds Firm As Trump Reinstates Hormuz Blockade: ORCL, SOUN, QTTB, FAC In Focus

Equity

“The U.S.A. will be, from this point forward, known as ‘THE GUARDIAN OF THE HORMUZ STRAIT,’” Trump said on social media.

QTTB Stock Clocks Best Day In A Year Following Positive Alopecia Data — Analyst Sees Further 200% Upside

Patients treated with bempikibart for 36 weeks saw a 35% average reduction in scalp hair loss severity, the company said. 

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire WALTHAM, Mass., July 13, 2026 WALTHAM, Mass., July 13, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a...

12 Health Care Stocks Moving In Monday's Intraday Session

Gainers

Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million.
Q32 Bio (NASDAQ:QTTB) stock rose 81.08% to $20.3.read more...

Transformational Deals and Breakthrough Data Take Center Stage

From a transformational merger and corporate restructuring at Twin Vee PowerCats, to encouraging Phase 2 clinical data from Q32 Bio, major oncology financing by Agenus, government-backed AI development at Pulsenmore, shareholder returns from LogProstyle, and new third-party testing validating Xeriant's advanced construction materials, this week's developments demonstrate the diverse catalysts capable of reshaping small-cap growth stories. $VEEE, $XERI, $PLSM, $LGPS, $QTTB, $AGEN

Q32 Bio Stock Soars After Patchy Hair Loss Study - Here's Why

Q32 Bio reported positive Phase 2a data for bempikibart in severe alopecia areata, showing hair regrowth and favorable safety.read more...

12 Health Care Stocks Moving In Monday's Pre-Market Session

Gainers

Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-market session. The company's market cap stands at $25.1 million.
Q32 Bio (NASDAQ:QTTB) stock rose 65.92% to $18.6. Theread more...

Q32 Bio's Breakthrough Hair-Loss Data Could Mark a Turning Point in the Race to Transform Alopecia Treatment

Positive clinical data can rapidly change the outlook for an emerging biotechnology company, and Q32 Bio (NASDAQ:QTTB) may have delivered one of its most important milestones to date. The clinical-stage biotech announced encouraging 36-week topline results from Part B of its Phase 2a SIGNAL-AA trial evaluating bempikibart for patients with severe or very severe alopecia areata—a disease affecting roughly 700,000 people in the United States with limited treatment options.

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata

Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata Q32 Bio Announces Positive 36-Week Topline Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata PR Newswire WALTHAM, Mass., July 13, 2026...

Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket

Gainers: Q32 Bio up 29.6%, Mint up 75.8%, Fast Track up 58.2%, eLong up 33.4%, Sobr Safe up 29.2%, Eshallgo up 20.3%, Curis up 10.9%, Sky Quarry up 10.6%, Accuray up 9.5%, Bitzero up 5.5%. Losers: Global Mofy down 25.3%, Jiuzi down 22.1%, Julong down 21.4%, Haoxi down 20.4%, Sadot down 20.4%.read...

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

Traders are intensely debating the impact of a potential $200 million public offering on the share price following the recent trial results.

Investor sentiment is surging due to positive Phase 2a clinical data for bempikibart, despite skepticism regarding trial size and future efficacy.

Market participants are actively tracking the low float and analyst price target upgrades as bulls hope to force a violent move against bearish positions.

Rapid intraday price swings between $15 and $23 have sparked a high-stakes battle between momentum chasers and those expecting a rug pull.

Current Price	$21.38
Prev Close	$11.21
Open	$18.31
Dividend Yield	0.00%
50-Day Moving Average	$10.24
Beta	0.34
Avg. Volume	549,378.70
PE Ratio	8.03

52-Week High	$22.50
52-Week Low	$1.57
Market Capitalization	$265.47M
EPS (Annual)	$2.42
Price to Book	6.75
Revenue Per Employee	$2.24M

Feed

News

Sentiment

Earnings

Fundamentals

Info

QTTBQ32 Bio Inc.

Latest QTTB News